DLK1, delta-like 1 homolog (Drosophila), regulates tumor cell differentiation in vivo

Cancer Letters

Volumn 318, Issue 1, 2012, Pages 26-33

  Begum, Asma ^a   Kim, Yuri ^b   Lin, Qun ^a   Yun, Zhong ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ewha Womans University   (South Korea)

Author keywords

Cancer stem cell; Differentiation; DLK1; Hypoxia; Neuroblastoma

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL HYPOXIA; CONTROLLED STUDY; DELTA LIKE 1 HOMOLOG GENE; ENZYME ACTIVATION; ENZYME MECHANISM; ENZYME PHOSPHORYLATION; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE LOCATION; GENE OVEREXPRESSION; GENETIC MARKER; GROWTH REGULATION; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MALE; MOLECULAR PATHOLOGY; MOUSE; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA; NONHUMAN; PHENOTYPIC VARIATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GENE; TUMOR XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CELL DIFFERENTIATION; CELL PROLIFERATION; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOENZYME TECHNIQUES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA;

EID: 84857138547     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.11.032     Document Type: Article

References (45)

1. Reya T., Clevers H. Wnt signalling in stem cells and cancer. Nature 2005, 434:843-850.
2. Pardal R., Clarke M.F., Morrison S.J. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 2003, 3:895-902.
3. Valk-Lingbeek M.E., Bruggeman S.W., van Lohuizen M. Stem cells and cancer the polycomb connection. Cell 2004, 118:409-418.
4. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
5. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
6. Lin Q., Yun Z. Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics. Cancer Biol. Ther. 2010, 9:949-956.
7. Wagemaker G. Heterogeneity of radiation sensitivity of hemopoietic stem cell subsets. Stem Cells 1995, 13(Suppl. 1):257-260.
8. Phillips H.S., Kharbanda S., Chen R., Forrest W.F., Soriano R.H., Wu T.D., Misra A., Nigro J.M., Colman H., Soroceanu L., Williams P.M., Modrusan Z., Feuerstein B.G., Aldape K. Molecular subclasses of high-grade glioma predict prognosis Delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
9. Kim Y., Lin Q., Zelterman D., Yun Z. Hypoxia-regulated delta-like 1 homologue enhances cancer cell stemness and tumorigenicity. Cancer Res. 2009, 69:9271-9280.
10. Floridon C., Jensen C.H., Thorsen P., Nielsen O., Sunde L., Westergaard J.G., Thomsen S.G., Teisner B. Does fetal antigen 1 (FA1) identify cells with regenerative, endocrine and neuroendocrine potentials? A study of FA1 in embryonic Fetal, and placental tissue and in maternal circulation. Differentiation 2000, 66:49-59.
11. Kim Y., Lin Q., Glazer P.M., Yun Z. Hypoxic tumor microenvironment and cancer cell differentiation. Curr. Mol. Med. 2009, 9:425-434.
12. Burdon T., Stracey C., Chambers I., Nichols J., Smith A. Suppression of SHP-2 and ERK signalling promotes self-renewal of mouse embryonic stem cells. Develop. Biol. 1999, 210:30-43.
13. Burdon T., Smith A., Savatier P. Signalling Cell cycle and pluripotency in embryonic stem cells. Trends Cell Biol. 2002, 12:432-438.
14. Casanova E.A., Shakhova O., Patel S.S., Asner I.N., Pelczar P., Weber F.A., Graf U., Sommer L., Burki K., Cinelli P. Pramel7 mediates LIF/STAT3-dependent self-renewal in embryonic stem cells. Stem Cells 2011, 29:474-485.
15. Ross R.A., Spengler B.A., Domenech C., Porubcin M., Rettig W.J., Biedler J.L. Human neuroblastoma I-type cells are malignant neural crest stem cells. Cell Growth Differ. 1995, 6:449-456.
16. Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.F., Biedler J.L., Cheung N.K., Ross R.A. Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia 2004, 6:838-845.
17. Jogi A., Ora I., Nilsson H., Poellinger L., Axelson H., Pahlman S. Hypoxia-induced dedifferentiation in neuroblastoma cells. Cancer Lett. 2003, 197:145-150.
18. Lin Q., Lee Y.J., Yun Z. Differentiation arrest by hypoxia. J. Biol. Chem. 2006, 281:30678-30683.
19. Pietras A., Gisselsson D., Ora I., Noguera R., Beckman S., Navarro S., Pahlman S. High levels of HIF-2α highlight an immature neural crest-like neuroblastoma cell cohort located in a perivascular niche. J. Pathol. 2008, 214:482-488.
20. Yun Z., Maecker H.L., Johnson R.S., Giaccia A.J. Inhibition of PPARγ2 gene expression by the HIF-1-regulated gene DEC1/Stra13: a mechanism for regulation of adipogenesis by hypoxia. Dev. Cell 2002, 2:331-341.
21. Berwick D.C., Calissano M., Corness J.D., Cook S.J., Latchman D.S. Regulation of Brn-3a N-terminal transcriptional activity by MEK1/2-ERK1/2 signalling in neural differentiation. Brain Res. 2009, 1256:8-18.
22. Niles R.M. Signaling pathways in retinoid chemoprevention and treatment of cancer. Mutat. Res. 2004, 555:81-96.
23. Reynolds C.P., Matthay K.K., Villablanca J.G., Maurer B.J. Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 2003, 197:185-192.
24. Perri M., Pingitore A., Cione E., Vilardi E., Perrone V., Genchi G. Proliferative and anti-proliferative effects of retinoic acid at doses similar to endogenous levels in Leydig MLTC-1/R2C/TM-3 cells. Biochim. Biophys. Acta 2011, 1800:993-1001.
25. Hu L., Lind T., Sundqvist A., Jacobson A., Melhus H. Retinoic acid increases proliferation of human osteoclast progenitors and inhibits RANKL-stimulated osteoclast differentiation by suppressing RANK. PLoS One 2010, 5:e13305.
26. Zauli G., Visani G., Vitale M., Gibellini D., Bertolaso L., Capitani S. All-trans retinoic acid shows multiple effects on the survival, proliferation and differentiation of human fetal CD34+ haemopoietic progenitor cells. Br. J. Haematol. 1995, 90:274-282.
27. Enomoto M., Pan H., Suzuki F., Takigawa M. Physiological role of vitamin A in growth cartilage cells: low concentrations of retinoic acid strongly promote the proliferation of rabbit costal growth cartilage cells in culture. J. Biochem. 1990, 107:743-748.
28. Laborda J. The role of the epidermal growth factor-like protein dlk in cell differentiation. Histol. Histopathol. 2000, 15:119-129.
29. Smas C.M., Sul H.S. Pref-1 A protein containing EGF-like repeats, inhibits adipocyte differentiation. Cell 1993, 73:725-734.
30. Tornehave D., Jensen C.H., Teisner B., Larsson L.I. FA1 immunoreactivity in endocrine tumours and during development of the human fetal pancreas; negative correlation with glucagon expression. Histochem. Cell Biol. 1996, 106:535-542.
31. Van Limpt V.A., Chan A.J., Van Sluis P.G., Caron H.N., Van Noesel C.J., Versteeg R. High delta-like 1 expression in a subset of neuroblastoma cell lines corresponds to a differentiated chromaffin cell type. Int. J. Cancer 2003, 105:61-69.
32. Laborda J., Sausville E.A., Hoffman T., Notario V. Dlk A putative mammalian homeotic gene differentially expressed in small cell lung carcinoma and neuroendocrine tumor cell line. J. Biol. Chem. 1993, 268:3817-3820.
33. Yin D., Xie D., Sakajiri S., Miller C.W., Zhu H., Popoviciu M.L., Said J.W., Black K.L., Koeffler H.P. DLK1: increased expression in gliomas and associated with oncogenic activities. Oncogene 2006, 25:1852-1861.
34. Li L., Forman S.J., Bhatia R. Expression of DLK1 in hematopoietic cells results in inhibition of differentiation and proliferation. Oncogene 2005, 24:4472-4476.
35. Sakajiri S., O'Kelly J., Yin D., Miller C.W., Hofmann W.K., Oshimi K., Shih L.Y., Kim K.H., Sul H.S., Jensen C.H., Teisner B., Kawamata N., Koeffler H.P. Dlk1 in normal and abnormal hematopoiesis. Leukemia 2005, 19:1404-1410.
36. Khoury H., Suarez-Saiz F., Wu S., Minden M.D. An upstream insulator regulates DLK1 imprinting in AML. Blood 2010, 115:2260-2263.
37. Yanai H., Nakamura K., Hijioka S., Kamei A., Ikari T., Ishikawa Y., Shinozaki E., Mizunuma N., Hatake K., Miyajima A. Dlk-1 A cell surface antigen on foetal hepatic stem/progenitor cells, is expressed in hepatocellular, colon, pancreas and breast carcinomas at a high frequency. J. Biochem. 2010, 148:85-92.
38. Villena J.A., Kim K.H., Sul H.S. Pref-1 and ADSF/resistin: two secreted factors inhibiting adipose tissue development. Horm. Metab. Res. 2002, 34:664-670.
39. Chen L., Qanie D., Jafari A., Taipaleemaki H., Jensen C.H., Sanz M.L., Laborda J., Abdallah B.M., Kassem M. Delta-like 1 / fetal antigen-1 (Dlk1/FA1) is a novel regulator of chondrogenic cell differentiation via inhibition of the AKT-dependent pathway. J. Biol. Chem. 2011.
40. Ferron S.R., Charalambous M., Radford E., McEwen K., Wildner H., Hind E., Morante-Redolat J.M., Laborda J., Guillemot F., Bauer S.R., Farinas I., Ferguson-Smith A.C. Postnatal loss of Dlk1 imprinting in stem cells and niche astrocytes regulates neurogenesis. Nature 2011, 475:381-385.
41. Nordsmark M., Overgaard J. Tumor hypoxia is independent of hemoglobin and prognostic for loco-regional tumor control after primary radiotherapy in advanced head and neck cancer. Acta Oncol. 2004, 43:396-403.
42. Brizel D.M., Dodge R.K., Clough R.W., Dewhirst M.W. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother. Oncol. 1999, 53:113-117.
43. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 1996, 56:4509-4515.
44. Yun Z., Lin Q., Giaccia A.J. Adaptive myogenesis under hypoxia. Mol. Cell. Biol. 2005, 25:3040-3055.
45. Gustafsson M.V., Zheng X., Pereira T., Gradin K., Jin S., Lundkvist J., Ruas J.L., Poellinger L., Lendahl U., Bondesson M. Hypoxia requires notch signaling to maintain the undifferentiated cell state. Dev. Cell 2005, 9:617-628.